Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study

In the treatment of Peg IFNα-2b combined with NAs (Peg IFN combined treatment group), the treatment of Peg IFNα-2b should be no less than 48 weeks. The initial therapeutic dose of Peg IFNα-2b and the subsequent adjusted dose will be individualized determined by clinicians based on the specific condition of the patients. In the NAs monotherapy group, entecavir (ETV), tenofovir fumarate disoproxil (TDF), tenofovir propofol fumarate (TAF), and emitenofovir (TMF) were used for treatment for no less than 48 weeks, and Peg IFN was not added or switched for treatment.